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The Antifungal Activity of Lactoferrin
and Its Derived Peptides:
Mechanisms of Action and Synergy
with Drugs against Fungal Pathogens
Kenya E. Fernandes and Dee A. Carter *
School of Life and Environmental Sciences, University of Sydney, Sydney, NSW, Australia
Lactoferrin is a multifunctional iron-binding glycoprotein belonging to the transferrin
family. It is found abundantly in milk and is present as a major protein in human exocrine
secretions where it plays a role in the innate immune response. Various antifungal
functions of lactoferrin have been reported including a wide spectrum of activity across
yeasts and molds and synergy with other antifungal drugs in combination therapy, and
various modes of action have been proposed. Bioactive peptides derived from lactoferrin
can also exhibit strong antifungal activity, with some surpassing the potency of the whole
protein. This paper reviews current knowledge of the spectrum of activity, proposed
mechanisms of action, and capacity for synergy of lactoferrin and its peptides, including
the three most studied derivatives: lactoferricin, lactoferrampin, and Lf(1–11), as well as
some lactoferrin-derived variants and modified peptides.
Keywords: lactoferrin, lactoferricin, lactoferrampin, Lf(1–11), antimicrobial peptides, natural products, fungi,
synergy
INTRODUCTION
The rising incidence of severe fungal infections, due largely to increased numbers of
immunocompromised patients, has made the discovery of new compounds that have effective
antifungal activity or that support the activity of currently used antifungal agents more important
than ever. Natural products are a significant source of novel antimicrobial compounds, and an
increasing number are being identified from mammalian sources including milk proteins. One
example is the multifunctional iron-binding glycoprotein, lactoferrin (Lf), and its various derived
peptides. This article will focus on the spectrum of antifungal activity shown by Lf when used alone
and in combination with other antifungal drugs, and will review currently proposed mechanisms
of antifungal action for Lf and its derived peptides.
First identified almost 80 years ago in bovine milk (Sorensen and Sorensen, 1939) and later
isolated and purified from humans and cows in 1960 (Groves, 1960), Lf is produced by various
mammals including pigs, goats, dogs, mice, and horses (Lönnerdal and Iyer, 1995; Garcia-Montoya
et al., 2012). In humans, it is a major protein secreted by the epithelial cells into exocrine fluids such
as tears, saliva, vaginal fluids, gastrointestinal fluids, bile, urine, and sweat (Masson et al., 1968; van
der Strate et al., 2001; González-Chávez et al., 2009; Park et al., 2011) but is present at the highest
concentrations in human colostrum and breast milk (Lönnerdal and Iyer, 1995). Lf is involved
in various physiological functions including iron regulation and the innate immune response,
and has been demonstrated to have anti-inflammatory, anti-oxidant, anti-allergic, and anti-cancer
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properties (Conneely, 2001; Kruzel et al., 2006; Actor et al., 2009;
Iigo et al., 2009; Burrow et al., 2011; Ogasawara et al., 2014) in
addition to antimicrobial activity against a wide range of fungal,
bacterial, viral, and parasitic pathogens (Jenssen and Hancock,
2009; Leboffe et al., 2009; Berlutti et al., 2011; Giansanti et al.,
2013). The ability to bind and sequester iron is an important
component of the antimicrobial activity of Lf (Jenssen and
Hancock, 2009).
In addition to being an active intact protein, Lf is a rich source
of antimicrobial peptides that are cleaved from the polypeptide
chain by various proteolytic enzymes. As many of these enzymes
are present in various body sites in humans, it is expected that
a number of the cleaved peptides contribute to the normal
functions of Lf in the body (Sinha et al., 2013). An increasing
number of Lf-derived peptides are also being generated and
modified by chemical synthesis (van der Kraan et al., 2005a).
Many Lf peptides exhibit a broad spectrum of antimicrobial
activity, have various different structural elements and modes
of action, and appear to perform numerous functions including
modulation of the inflammatory response, and stimulation of
apoptosis (Farnaud et al., 2004; Sánchez-Gómez et al., 2008; van
der Does et al., 2012).
STRUCTURE AND ANTIFUNGAL ACTIVITY
OF WHOLE LACTOFERRIN
The structure of Lf consists of a single polypeptide chain
containing ∼700 amino acids folded into two globular lobes.
These lobes are highly homologous to each other and are
connected by an α-helical residue providing flexibility to the Lf
molecule. Each lobe consists of two domains forming a single
iron binding site, allowing each Lf molecule to strongly bind two
ferric ions (Anderson et al., 1989). The open, iron-free form of
Lf is known as apo-Lf while the closed, iron-rich form is holo-
Lf, which differs in tertiary structure and is more resistant to
proteolysis than apo-Lf (Jameson et al., 1998). In addition to
binding Fe3+, Lf has also been observed to bind a range of other
compounds including lipopolysaccharides, heparin, DNA, and
metal ions including Cu2+, Zn2+, and Mn2+ (Baker, 1994).
Lf is most commonly purified from human (hLf) or bovine
(bLf) milk but it has also been obtained from the milk
and colostrum of several other mammals. Recombinant Lf
(rLf) is increasingly being generated from microbial expression
systems and through transgenic plants and animals (Lönnerdal
and Iyer, 1995). Lf molecules from across species are highly
homologous but have varying antifungal activity owing to small
differences in structure. Furthermore, the level of activity of Lf
with similar purities can vary substantially between different
producers, ranging from reasonably active to inactive in the same
test organism. bLf in particular has well-documented activity
against a range of human and plant fungal pathogens including
yeasts and molds (Table 1). Most widely studied is its activity
on members of the Candida species, with Candida tropicalis,
Candida krusei, and Candida albicans exhibiting the highest level
of susceptibility while Candida glabrata has the lowest (Nikawa
et al., 1993; Xu et al., 1998).
Early studies with Candida species attributed the antifungal
effect of Lf to its ability to sequester iron resulting in a
fungistatic effect (Kirkpatrick et al., 1971), and inhibition of
growth of Candida and Cryptococcus can be rescued by the
addition of iron (Al-Sheikh, 2009; Lai et al., 2016). In Aspergillus
fumigatus, the sequestration of Fe3+ by apo-Lf was shown to
be important for host defense (Zarember et al., 2007) indicating
that iron sequestration can play a role in the antifungal action
of Lf in vivo. More recent studies now suggest that the main
antifungal mechanism of Lf is iron-independent and occurs
through a direct interaction of Lf with the fungal cell surface,
leading to cell membrane damage and leakage. Supernatant
protein assays and propidium iodide staining have shown that
Lf alters cell surface permeability in C. albicans, C. krusei, and
Cryptococcus neoformans, leading to cell death (Nikawa et al.,
1993; Wakabayashi et al., 1996; Kondori et al., 2011). Alterations
to the cell surface itself including protein leakage, the formation
of surface blebs, swelling, and cell collapse have been seen in
Candida isolates through scanning electron microscopy (Nikawa
et al., 1993; Wakabayashi et al., 1996; Xu et al., 1998; van der
Kraan et al., 2005b).
The cellular release of potassium ions, cytosolic acidification,
changes in membrane potential, intracellular ROS accumulation,
and chromatin condensation have all been detected in C. albicans
following treatment with Lf indicating the induction of an
apoptotic phenotype (Viejo-Díaz et al., 2004; Andres et al., 2008).
The details by which Lf induces apoptosis-like processes in fungi
remain largely unclear, however, recent studies have examined
this mechanism in significant yeast species. In Saccharomyces
cerevisiae, it was shown that hLf induces cell death in a
mitochondrial and caspase-dependent way that is characterized
by caspase activation, ROS accumulation and cytochrome c
release (Acosta-Zaldivar et al., 2016). Work by the same group
in C. albicans indicated that the proton-translocating ATPase
Pma1p, which is a primary contributor to pH regulation in yeasts,
was the target of hLf, inducing lethal mitochondrial dysfunction
(Andres et al., 2016).
The combined use of Lf with other antifungal drugs has
been increasingly studied in recent years. When combined
with fluconazole, various sources of Lf have been observed
to significantly enhance inhibitory activity and decrease the
minimum inhibitory concentration (MIC) for several Candida
species, including wild type and clinical strains, and ergosterol
biosynthesis and azole-resistant mutants (Wakabayashi et al.,
1998; Kuipers et al., 1999; Naidu et al., 2004; Venkatesh and Rong,
2008; Kobayashi et al., 2011). The mechanism of synergy between
Lf and fluconazole is not yet well-understood and does not appear
to result from an increased intracellular uptake of fluconazole, as
the intracellular concentration of radiolabelled fluconazole was
not affected by the addition of bLf (Kobayashi et al., 2011).
Several other azole drugs, including itraconazole,
clotrimazole, and ketoconazole, as well as 5-fluorocytosine
have been demonstrated to function synergistically with Lf in
C. albicans (Wakabayashi et al., 1996; Kuipers et al., 1999).
The polyene drugs amphotericin B and nystatin exhibited
no interactions with bLf when tested in Candida species
(Wakabayashi et al., 1996) although amphotericin B and
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TABLE 1 | Antifungal spectrum of activity of Lf and derived peptides.
Position in Lf Peptide Source Test organism Inhibitory conc.‡ References
Whole protein Lactoferrin Bovine Aspergillus niger IC50 = 578 µg/mL Nikawa et al., 1993;
Wakabayashi et al., 1998; Xu
et al., 1998; Kuipers et al.,
1999; Lahoz et al., 2008; Lai
et al., 2016
Candida albicans* MIC = 200–>6400 µg/mL
Candida glabrata* MIC = >6000 µg/mL
Candida guilliermondii* MIC not determined
Candida krusei* IC50 = 20 µg/mL
Candida parapsilosis* MIC not determined
Candida tropicalis* MIC not determined
Cryptococcus gattii* MIC = 64 µg/mL
Cryptococcus neoformans* MIC = 64 µg/mL
Phoma exigua IC50 = 821 µg/mL
Rhizoctonia solani IC50 = 121 µg/mL
Saccharomyces cerevisiae MIC = 16 µg/mL
Sclerotium rolfsii IC50 = 231 µg/mL
Sclerotinia sclerotiorum IC50 = 31 µg/mL
Trichoderma viride IC50 = 952 µg/mL
1–11 Lf(1–11) Human Candida albicans MIC not determined Lupetti et al., 2000, 2008
Aspergillus fumigatus MIC = 4.3 µM
16–40 HLBD1 Human Candida albicans MMC = 6.2 µg/ml Kondori et al., 2011
17–26 Peptide 2 Bovine Candida albicans* MIC = 17.3–17.5 µM Ueta et al., 2001
17–30 bLf 17–30 Bovine Candida albicans* MIC = 5–10 µM van der Kraan et al., 2004
17–31 Lfcin B 17–31 Bovine Alternatria sp. MIC = 16 µM Muñoz and Marcos, 2006;
Enrique et al., 2007Aspergillus nidulans MIC = 4 µM
Botrytis cinerea MIC = 16 µM
Dekkera bruxellensis* MIC = 3.75–20 µM
Fusarium oxysporum MIC = 8 µM
Penicillium digitatum MIC = 4 µM
Penicillium expansum MIC = 8 µM
Penicillium italicum MIC = 4 µM
Pichia membranifaciens MIC not determined
Saccharomyces cerevisiae MIC = 32 µM
Zygosaccharomyces bailii MIC = 8 µM
Zygosaccharomyces bisprous MIC = 12 µM
17–31 Lfcin H 17–31 Human Candida albicans MIC = 10 µg/ml Håversen et al., 2010
17–41 Lactoferricin Bovine Absidia corymbifera* MIC = 40 µg/ml Bellamy et al., 1993, 1994;
Wakabayashi et al., 1996,
1998, 1999
Aspergillus versicolor MIC = 10 µg/ml
Candida albicans* MIC = 0.8–400 µg/ml
Candida glabrtata* MIC = 80–120 µg/ml
Candida guilliermondii* MIC = 5–40 µg/ml
Candida kefyr* MIC = 2.5–10 µg/ml
Candida krusei* MIC = 10–20 µg/ml
Candida parapsilosis* MIC = 7.8–80 µg/ml
Candida tropicalis* MIC = 0.31–1.25 µg/ml
Cladosporium trichoides* MIC = 5 µg/ml
Cryptococcus albidus MIC = 24 µg/ml
Cryptococcus curvatus MIC = 9 µg/ml
Cryptococcus neoformans* MIC = 0.63 µg/ml
Cryptococcus uniguttulatus MIC = 6 µg/ml
Epidermophyton floccosum MIC = 0.31–2.5 µg/ml
Exophiala dermatitidis* MIC = 2 µg/ml
(Continued)
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TABLE 1 | Continued
Position in Lf Peptide Source Test organism Inhibitory conc.‡ References
Fonsecaea pedrosoi MIC = 5 µg/ml
Fusarium moniliforme* MIC = 2.5–5 µg/ml
Microsporum canis MIC = 40 µg/ml
Microsporum gypseum MIC = 20–40 µg/ml
Nannizia gypsea MIC = 30 µg/ml
Nannizzia incurvata MIC = 18 µg/ml
Nannizzia otae MIC = 60 µg/ml
Paracoccidioides brasiliensis* MIC = 0.63–1.25 µg/ml
Penicillium pinophilum MIC = 45 µg/ml
Penicillium vermiculatum MIC = 45 µg/ml
Phialophora verrucosa* MIC = 5–10 µg/ml
Saccharomyces cerevisiae MIC = 0.63 µg/ml
Sporothrix schenckii MIC = 2–10 µg/ml
Trichophyton mentagrophytes* MIC = 6.3–45 µg/ml
Trichophyton rubrum* MIC = 13–60 µg/ml
Trichophyton tonsurans* MIC = 5–40 µg/ml
Trichophyton violaceum* MIC = 40 µg/ml
Trichosporon cutaneum* MIC = 1.25–18 µg/ml
18–31 Lfcin 18–31 Human Candida albicans MIC = 10 µg/ml Håversen et al., 2010
18–37 Lfcin B-20 Bovine Candida albicans MIC = 8 µg/ml Chen et al., 2006
18–37 Lfcin P-20 Porcine Candida albicans MIC = 32 µg/ml Chen et al., 2006
18–40 Lfpep Human Candida albicans MIC = 18.7 µM Viejo-Diaz et al., 2005
Candida glabrata MIC = 9.3 µM
Candida guilliermondii MIC = 9.3 µM
Candida krusei MIC = 4.7 µM
Candida parapsilosis MIC = 9.3 µM
Candida tropicalis MIC = 9.3 µM
18–42 Lfcin B 18–42 Bovine Candida albicans MIC = 100 µg/ml Wakabayashi et al., 1999
Trichophyton mentagrophytes MIC = 12 µg/ml
19–31 Lfcin 19–31 Human Candida albicans MMC = 200 µg/ml Håversen et al., 2010
19–38 Lfcin H-20 Human Candida albicans MIC = 256 µg/ml Chen et al., 2006
20–25 Lfcin B 20–25 Bovine Saccharomyces cerevisiae MIC = >48 µM Muñoz and Marcos, 2006;
Enrique et al., 2007Dekkera bruxellensis MIC not determined
Pichia membranifaciens MIC not determined
Zygosaccharomyces bailii MIC not determined
Zygosaccharomyces bisporus MIC not determined
Cryptococcus albidus MIC not determined
Penicillium digitatum MIC = 8 µM
Penicillium italicum MIC = 8 µM
Penicillium expansum MIC = 16 µM
Penicillium sp. MIC = 32 µM
Aspergillus nidulans MIC = 8 µM
Botrytis cinerea MIC = 16 µM
Fusarium oxysporum MIC = 16 µM
20–28 Lfcin B-9 Bovine Candida albicans* MIC = 25–32 µg/ul Wakabayashi et al., 1999;
Chen et al., 2006Trichophyton mentagrophytes MIC = 6 µg/ul
20–28 Lfcin P-9 Porcine Candida albicans MIC = 512 µg/ml Chen et al., 2006
20–31 HL10 Human Candida albicans* MMC = 100–200 µg/ml Håversen et al., 2010;
Kondori et al., 2011Candida parapsilosis* MMC = 100–200 µg/ml
Candida kefyr MMC = 100 µg/ml
(Continued)
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TABLE 1 | Continued
Position in Lf Peptide Source Test organism Inhibitory conc.‡ References
Candida krusei MMC = 100 µg/ml
Candida neoformans* MMC = 50 µg/ml
21–26 Peptide 5 Bovine Candida albicans* MIC = 500 µM Ueta et al., 2001
21–29 Lfcin H-9 Human Candida albicans MIC = 256 µg/ml Chen et al., 2006
30–41 Peptide3 Bovine Candida albicans* MIC = 635 µM Ueta et al., 2001
152–182 Kaliocin-1 Human Candida albicans MIC = 150 µM Viejo-Diaz et al., 2005
Candida glabrata MIC = 150 µM
Candida guilliermondii MIC = 150 µM
Candida krusei MIC = 150 µM
Candida parapsilosis MIC = 150 µM
Candida tropicalis MIC = 150 µM
259–284 Lfampin 259–284 Bovine Candida albicans LC50 = 2.3 µM Bolscher et al., 2006
261–284 Lfampin 261–284 Bovine Candida albicans LC50 = 1.8 µM van der Kraan et al., 2005a
263–284 Lfampin 263–284 Bovine Candida albicans LC50 = 0.7 µM van der Kraan et al., 2005a
264–284 Lfampin 264–284 Bovine Candida albicans LC50 = 1.8 µM van der Kraan et al., 2005a
265–278 Lfampin 265–278 Bovine Candida albicans LC50 = >100 µM van der Kraan et al., 2005a
265–280 Lfampin 265–280 Bovine Candida albicans LC50 = 39 µM van der Kraan et al., 2005a
265–282 Lfampin 265–282 Bovine Candida albicans LC50 = 5.2 µM van der Kraan et al., 2005a
265–284 Lfampin 265–284 Bovine Candida albicans LC50 = 0.7 µM Bolscher et al., 2006
265–296 Lfampin 265–296 Bovine Candida albicans LC50 = 0.5 µM Bolscher et al., 2006
266–284 Lfampin 266–284 Bovine Candida albicans LC50 = 1.4 µM van der Kraan et al., 2005a
266–286 Cap-LFampinH-K Human Candida albicans MIC not determined Haney et al., 2009
268–284 Lactoferrampin Bovine Candida albicans MIC = 4.3 µg/ml van der Kraan et al., 2005a
269–286 LFampinH-K Human Candida albicans MIC not determined Haney et al., 2009
270–284 Lfampin 270–284 Bovine Candida albicans LC50 = 26 µM van der Kraan et al., 2005a
Unknown Hydrolysate Human Penicillium sp. MIC = 60–300 µg/mL Liceaga-Gesualdo et al., 2001
*Indicates multiple strains were tested within species.
‡
IC50, Inhibitory Concentration (50% Inhibition); LC50, Lethal Concentration (50%Mortality); MIC, Minimum Inhibitory Concentration;
MMC, Minimum Microbiocidal Concentration. As different studies have used varying methods and sources of lactoferrin to determine inhibitory concentrations, these values may not
be comparable between studies.
bLf have been found to act synergistically in Cryptococcus
neoformans, Cryptococcus gattii, and S. cerevisiae. The addition
of exogenous iron did not rescue growth of Cryptococcus treated
with amphotericin B and bLf, indicating that the mechanism of
synergy is not solely due to iron chelation (Lai et al., 2016).
STRUCTURE AND ANTIFUNGAL ACTIVITY
OF LACTOFERRICIN—THE MAJOR
PEPTIDE DERIVED FROM LACTOFERRIN
Lactoferricin (Lfcin) is found in the human gut as a natural
breakdown product and was first generated by Bellamy et al.
(1992) through pepsin hydrolysis of intact Lf. Bovine lactoferricin
(bLfcin), comprising residues 17–41 from the N-terminal region
of Lf, is simpler in structure but much more potent than
human lactoferricin (hLfcin), which comprises residues 1–47.
Both Lfcins possess an 18-residue loop region with a disulphide
bridge and many positively charged and hydrophobic residues
(Gifford et al., 2005).
The three dimensional structures of hLfcin and bLfcin differ
from each other and from the homologous regions of the
intact Lf protein, and it is thought these differences determine
their different antifungal efficacies. While bLfcin forms a β-
sheet confirmation in solution that contains a group of aligned
hydrophobic residues well-suited to interactions with biological
membranes, hLfcin forms a coiled structure in solution lacking
the aligned residues and thus having weaker interactions with the
target cell (Farnaud et al., 2004; Hunter et al., 2005; Alexander
et al., 2012). Lfcin shows strongly enhanced antimicrobial activity
compared to Lf and the antifungal efficacy of bLfcin, in particular,
has been observed across a large range of various types of fungi
(Table 1).
The primary antifungal mechanism of action of Lfcin appears
to be through direct interaction with the fungal surface and
disruption of the fungal membrane (Bellamy et al., 1993).
Using confocal scanning laser microscopy, it was observed
that bLfcin molecules were internalized by C. albicans cells
within minutes (van der Kraan et al., 2005b) and that
treatment with Lfcin resulted in dissipation of the proton
gradient across the cell membrane (Gifford et al., 2005). In C.
albicans and in the dermatophyte Trichophyton mentagrophytes,
changes in ultrastructural features and an aggregation of
cytoplasmic materials observed following treatment with Lfcin
Frontiers in Microbiology | www.frontiersin.org 5 January 2017 | Volume 8 | Article 2
Fernandes and Carter Antifungal Activity of Lactoferrin and Its Peptides
were traced to stimulation of ATP synthesis and extracellular
secretion, resulting in pore formation in the plasma membrane
(Bellamy et al., 1994; Ueta et al., 2001). Lfcin has also
been shown to upregulate host defense via the induction of
reactive oxygen species that stimulate the fungicidal activities
of polymorphonuclear leukocytes (Kullberg et al., 1999). This
ability to mount a combined assault on microbial pathogens is
a common feature of natural host-derived products, most likely
resulting from evolutionary pressures to maintain efficacy and
prevent pathogens from developing resistance (Xu et al., 2009;
Carter et al., 2016).
Synergy between bLfcin and azole antifungal drugs has been
observed in C. albicans. In azole-resistant strains, the addition of
low levels of bLfcin greatly increased inhibition by fluconazole
and itraconazole and was seen to inhibit the growth of fungal
hyphae (Wakabayashi et al., 1998). bLfcin has also been observed
to function synergistically with clotrimazole and ketoconazole
and it significantly reduced the formation of biofilms when
used in combination with voriconazole and amphotericin B
(Wakabayashi et al., 1996). The mechanistic basis of these
synergistic actions remains unknown.
ANTIFUNGAL ACTIVITY OF OTHER
LACTOFERRIN-DERIVED PEPTIDES
Lactoferrampin
Lactoferrampin (Lfampin), comprising residues 268–284 in the
N1 domain of Lf, is located in close proximity to Lfcin in
the tertiary structure of Lf. Identified as a molecule of interest
due to its net positive charge and possession of a hydrophobic
domain, Lfampin is thought to play a role in membrane-
mediated activities of Lf (van der Kraan et al., 2004). Lfampin
has demonstrated antifungal efficacy against C. albicans and is
known to be more potent than Lf but has not yet been tested with
a wide range of fungal organisms (Table 1). Similarly, whether
Lfampin acts synergistically with antifungal drugs has not yet
been determined.
Like Lfcin, the mechanism of action of Lfampin is by binding
to and disrupting the cell membrane, and it was similarly
observed to be internalized within a few minutes by C. albicans,
resulting in membrane permeabilisation and the formation of
vesicle-like structures (van der Kraan et al., 2005b). However,
Lfampin differs greatly from Lfcin in amino acid composition,
structure and orientation. In solution, the first 11 residues of
bovine lactoferrampin (bLfampin) form an α-helical structure
(Haney et al., 2007). A tryptophan residue in the N-terminal
region has been shown to interact with model membranes and
is contained in all varieties of Lfampin from different sources
involved in membrane insertion indicating that it is responsible
for this function (Haney et al., 2007; Sinha et al., 2013).
Lf(1–11)
The Lf(1–11) peptide comprises the first 11 amino acid residues
of the N-terminal region of Lf and exhibits antifungal activity
against C. albicans and A. fumigatus (Table 1; Lupetti et al.,
2000). The mechanism of action of Lf(1–11) also appears to
rely on interactions with the fungal membrane, with important
structural features including its highly cationic nature and the
presence of hydrophobic valine (V6) and tryptophan (W8)
residues (Bruni et al., 2016). Lupetti et al. (2000) demonstrated
through residue substitution that the first two arginines at
the N-terminus (R2, R3) are also necessary for the antifungal
action of hLf(1–11) in C. albicans. hLf(1–11) appears to have
immunomodulatory properties during C. albicans infection
where it directs the differentiation of monocytes into dendritic
cells that enhance the polarization of a Th17 response, which is
an important component of the host defense against fungi (van
der Does et al., 2012).
When combined with fluconazole, a synergistic antifungal
effect has been seen across various Candida species including C.
glabrata, C. krusei, C. parapsilosis, C. tropicalis, and fluconazole-
resistant strains of C. albicans. At sub-inhibitory concentrations,
these yeasts were seen to be killed when preincubated with hLf(1–
11) before introducing fluconazole but not when fluconazole
was introduced first, indicating that hLf(1–11) is responsible
for initiating candidacidal activity while fluconazole acts
synergistically during a later stage (Lupetti et al., 2003).
Synthetic Peptides Based on Lactoferrin
A wide variety of other derivatives of varying size and location
have been generated from the whole Lf protein (Table 1). A
number of these peptides were created in an attempt to facilitate
the discovery of other antimicrobial sequences composed of short
core residues within Lf. As an example of this, Chen et al.
(2006) created and tested a range of short synthetic derivatives
of human, bovine, and porcine Lfcins in an attempt to discover
other antimicrobial sequences comprising core residues within
Lf. This enabled them to find the antimicrobial domain in Lfcin
of porcine origin, and to compare its potency to Lfcins of human
and bovine origin.
Lf derivatives have also been designed to help clarify the
relationship between structure and function of particular Lf-
derived peptides. In one study, by testing a collection of peptides
obtained by extending and/or truncating the C- or N- terminal
ends of Lfampin, it was demonstrated that the highest level of
antimicrobial activity corresponded with strongest membrane
interactions and greatest ability to form an α-helix (Adão et al.,
2011). In another study, a significant increase in candidacidal
activity was seen in an extended form of Lfampin due to
an increased positive charge near the C-terminal end (Haney
et al., 2009). These studies demonstrate that there is capacity
to optimize the activity of Lf-derived molecules by careful
consideration of their sequence and structural properties.
Modified and Lactoferrin-Like Peptides
In recent years, an increasing number of studies have taken the
path of modifying the original amino acid sequence of Lf peptides
in order to develop more potent antifungal activity than in the
parent peptides (Table 2). Various strategies designed to alter
properties related to antifungal activity have been employed in
the construction of these novel peptides such as modifying the
length, net charge, and hydrophobicity of the peptide.
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By the selective substitution of amino acids based on
hydrophobicity in groups of residues derived from the N-
terminal end of hLf, Kondori et al. (2011) and Mishra et al.
(2013) created HLopt2 and L10, respectively. Björn et al.
(2016) subsequently developed HLR1r from hLfcin by the
addition of an Arg-rich motif designed to facilitate membrane
interactions, together with capping of the N- and C- terminals
to make them neutral. These three peptides demonstrated potent
antifungal action against Candida species that was substantially
greater than that of the corresponding residues from the
native Lf peptide. Taking another approach, fusion peptides
have been generated synthetically from the combination of
multiple bioactive peptides: Lfchimera, a fusion of bLfcin and
Lfampin, and LFT33, a fusion of bLfcin and the insect-derived
antimicrobial peptide thanatin (Feng et al., 2012; Silva et al.,
2013).
In addition to modifications of the natural peptide, the
sequence of Lf has been used to search for other naturally
occurring peptides with high homology in order to facilitate
discovery of novel potential antifungals. The utility of this
approach was demonstrated by the discovery of LBLP, a peptide
with 34.4% similarity to bLfcin and produced from the bodies of
centipedes, which was found to have strong antifungal activity
against strains of Candida, Malassezia, and Trichosporon (Choi
et al., 2013).
SUMMARY AND CONCLUSIONS
Lf and its major naturally cleaved peptide, Lfcin, have proven
broad-spectrum antifungal action, with Lfcin exhibiting greater
potency than the intact protein. The less well-characterized
peptides including Lfampin and Lf(1–11) have also been seen to
possess increased antifungal potency in Candida species but have
not been tested extensively beyond this. Lf and Lfcin function
synergistically primarily with azole antifungal drugs, however,
knowledge of the spectrum and mechanism of these synergistic
interactions is lacking, and synergy is largely unexplored for the
other Lf-derived peptides.
Mechanistically, Lf and its peptides have been shown to
function primarily through membrane destabilization, with
immunomodulation and iron sequestration playing secondary
roles. Although many aspects of Lf-derived peptides are quite
conserved, differences in amino acid composition and tertiary
structure contribute to their different functional properties.
Novel alternative peptides that have been generated or modified
from the original sequence of Lf provide insight into the
relationship between structure and function. Lf and its
derived peptides have great potential as leads for future
antifungal drug development, however, considerable research
is still required to understand the antifungal actions of
these molecules as well as their potential to support current
antifungals.
AUTHOR CONTRIBUTIONS
This article was written by KF and was reviewed and edited
by DC.
FUNDING
Work on Lf in the Carter Lab has been supported by the
Australian National Health and Medical Research Council
(Grant Number APP1021267). KF is financially supported by an
Australian Postgraduate Award.
REFERENCES
Acosta-Zaldivar, M., Andres, M. T., Rego, A., Pereira, C. S., Fierro, J. F., and Corte-
Real, M. (2016). Human lactoferrin triggers a mitochondrial- and caspase-
dependent regulated cell death in Saccharomyces cerevisiae. Apoptosis 21,
163–173. doi: 10.1007/s10495-015-1199-9
Actor, J. K., Hwang, S. A., and Kruzel, M. L. (2009). Lactoferrin as
a natural immune modulator. Curr. Pharm. Des. 15, 1956–1973.
doi: 10.2174/138161209788453202
Adão, R., Nazmi, K., Bolscher, J. G., and Bastos, M. (2011). C- and N-
truncated antimicrobial peptides from LFampin 265-284: biophysical
versus microbiology results. J. Pharm. Bioallied Sci. 3, 60–69.
doi: 10.4103/0975-7406.76467
Alexander, D. B., Iigo, M., Yamauchi, K., Suzui, M., and Tsuda, H. (2012).
Lactoferrin: an alternative view of its role in human biological fluids. Biochem.
Cell Biol. 90, 279–306. doi: 10.1139/o2012-013
Al-Sheikh, H. (2009). Effect of lactoferrin and iron on the growth of
human pathogenic Candida species. Pak. J. Biol. Sci. 12, 91–94.
doi: 10.3923/pjbs.2009.91.94
Anderson, B. F., Baker, H. M., Norris, G. E., Rice, D. W., and Baker,
E. N. (1989). Structure of human lactoferrin: crystallographic structure
analysis and refinement at 2.8 A resolution. J. Mol. Biol. 209, 711–734.
doi: 10.1016/0022-2836(89)90602-5
Andres, M. T., Acosta-Zaldivar, M., and Fierro, J. F. (2016). Antifungal
mechanism of action of lactoferrin: identification of H+-ATPase (P3A-type)
as a new apoptotic-cell membrane receptor. Antimicrob. Agents Chemother. 60,
4206–4216. doi: 10.1128/AAC.03130-15
Andres, M. T., Viejo-Diaz, M., and Fierro, J. F. (2008). Human lactoferrin
induces apoptosis-like cell death in Candida albicans: critical role of K+-
channel-mediated K+ eﬄux. Antimicrob. Agents Chemother. 52, 4081–4088.
doi: 10.1128/AAC.01597-07
Baker, E. N. (1994). Structure and reactivity of transferrins. Adv. Inorg. Chem. 41,
389–463. doi: 10.1016/S0898-8838(08)60176-2
Bellamy, W., Takase, M., Wakabayashi, H., Kawase, K., and Tomita, M. (1992).
Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived
from theN-terminal region of bovine lactoferrin. J. Appl. Bacteriol. 73, 472–479.
doi: 10.1111/j.1365-2672.1992.tb05007.x
Bellamy, W., Wakabayashi, H., Takase, M., Kawase, K., Shimamura, S., and
Tomita, M. (1993). Killing of Candida albicans by lactoferricin B, a
potent antimicrobial peptide derived from the N-terminal region of bovine
lactoferrin. Med. Microbiol. Immunol. 182, 97–105. doi: 10.1007/BF001
89377
Bellamy, W., Yamauchi, K., Wakabayashi, H., Takase, M., Takakura, N.,
Shimamura, S., et al. (1994). Antifungal properties of lactoferricin B, a peptide
derived from the N-terminal region of bovine lactoferrin. Lett. Appl. Microbiol.
18, 230–233. doi: 10.1111/j.1472-765X.1994.tb00854.x
Berlutti, F., Pantanella, F., Natalizi, T., Frioni, A., Paesano, R., Polimeni, A.,
et al. (2011). Antiviral properties of lactoferrin - a natural immunity molecule.
Molecules 16, 6992–7018. doi: 10.3390/molecules16086992
Björn, C., Mahlapuu, M., Mattsby-Baltzer, I., and Håkansson, J. (2016). Anti-
infective efficacy of the lactoferrin-derived antimicrobial peptide HLR1r.
Peptides 81, 21–28. doi: 10.1016/j.peptides.2016.04.005
Bolscher, J. G., van der Kraan, M. I., Nazmi, K., Kalay, H., Grun, C. H., Van’t
Hof, W., et al. (2006). A one-enzyme strategy to release an antimicrobial
Frontiers in Microbiology | www.frontiersin.org 8 January 2017 | Volume 8 | Article 2
Fernandes and Carter Antifungal Activity of Lactoferrin and Its Peptides
peptide from the LFampin-domain of bovine lactoferrin. Peptides 27, 1–9.
doi: 10.1016/j.peptides.2005.06.012
Bruni, N., Capucchio, M. T., Biasibetti, E., Pessione, E., Cirrincione, S.,
Giraudo, L., et al. (2016). Antimicrobial activity of lactoferrin-related peptides
and applications in human and veterinary medicine. Molecules 21, 752.
doi: 10.3390/molecules21060752
Burrow, H., Kanwar, R. K., and Kanwar, J. R. (2011). Antioxidant enzyme activites
of iron-saturated bovine lactoferrin (Fe-blf) in human gut epithelial cells under
oxidative stress.Med. Chem. 7, 224–230. doi: 10.2174/157340611795564286
Carter, D. A., Blair, S. E., Cokcetin, N. N., Bouzo, D., Brooks, P., Schothauer,
R., et al. (2016). Therapeutic manuka honey: no longer so alternative. Front.
Microbiol. 7:569. doi: 10.3389/fmicb.2016.00569
Chen, H. L., Yen, C. C., Lu, C. Y., Yu, C. H., and Chen, C. M. (2006). Synthetic
porcine lactoferricin with a 20-residue peptide exhibits antimicrobial activity
against Escherichia coli, Staphylococcus aureus and Candida albicans. J. Agric.
Food Chem. 54, 3277–3282. doi: 10.1021/jf053031s
Choi, H., Hwang, J. S., and Lee, D. G. (2013). Antifungal effect and pore-
forming action of lactoferricin B like peptide derived from centipede
Scolopendra subspinipes mutilans. Biochim. Biophys. Acta 1828, 2745–2750.
doi: 10.1016/j.bbamem.2013.07.021
Conneely, O. M. (2001). Anti-inflammatory activites of lactoferrin. J. Am. Coll.
Nutr. 20, 389s. doi: 10.1080/07315724.2001.10719173
Enrique, M., Marcos, J. F., Yuste, M., Martinez, M., Valles, S., and Manzanares, P.
(2007). Antimicrobial action of synthetic peptides towards wine spoilage yeasts.
Int. J. Food Microbiol. 118, 318–325. doi: 10.1016/j.ijfoodmicro.2007.07.049
Farnaud, S., Spiller, C., Moriarty, L. C., Patel, A., Gant, V., Odell, E.
W., et al. (2004). Interactions of lactoferricin-derived peptides with
LPS and antimicrobial activity. FEMS Microbiol. Lett. 233, 193–199.
doi: 10.1111/j.1574-6968.2004.tb09482.x
Feng, X., Liu, C., Guo, J., Song, X., Li, J., Xu, W., et al. (2012). Recombinant
expression, purification, and antimicrobial activity of a novel hybrid
antimicrobial peptide LFT33. Appl. Microbiol. Biotechnol. 95, 1191–1198.
doi: 10.1007/s00253-011-3816-z
Garcia-Montoya, I. A., Cendon, T. S., Arevalo-Gallegos, S., and Rascon-Cruz, Q.
(2012). Lactoferrin a multiple bioactive protein: an overview. BIochi. Biophys.
Acta 1820, 226–236. doi: 10.1016/j.bbagen.2011.06.018
Giansanti, F., Leboffe, L., D’Elia, I., and Antonini, G. (2013). An update
on the antifungal activities of lactoferrin: new promising applications in
diagnostic, therapeutics and biotechnology. Anti Infect. Agents 11, 155–158.
doi: 10.2174/2211352511311020009
Gifford, J. L., Hunter, H. N., and Vogel, H. J. (2005). Lactoferricin: a lactoferrin-
derived peptide with antimicrobial, antiviral, antitumour, and immunological
properties. Cell. Mol. Life Sci. 62, 2588–2598. doi: 10.1007/s00018-005-5373-z
González-Chávez, S. A., Arevalo-Gallegos, S., and Rascon-Cruz, Q. (2009).
Lactoferrin: structure, function and applications. Int. J. Antimicrob. Agents 33,
301e301–301e308. doi: 10.1016/j.ijantimicag.2008.07.020
Groves, M. L. (1960). The isolation of a red protein from milk. J. Am. Chem. Soc.
82, 3345–3350. doi: 10.1021/ja01498a029
Haney, E. F., Lau, F., and Vogel, H. J. (2007). Solution structures and
model membrane interactions of lactoferrampin, an antimicrobial peptide
derived from bovine lactoferrin. BIochi. Biophys. Acta 1768, 2355–2364.
doi: 10.1016/j.bbamem.2007.04.018
Haney, E. F., Nazmi, K., Lau, F., Bolscher, J. G., and Vogel, H. J. (2009).
Novel lactoferrampin antimicrobial peptides derived from human lactoferrin.
Biochimie 91, 141–154. doi: 10.1016/j.biochi.2008.04.013
Håversen, L., Kondori, N., Baltzer, L., Hanson, L. A., Dolphin, G. T., Duner, K.,
et al. (2010). Structure-microbicidal activity relationship of synthetic fragments
derived from the antibacterial alpha-helix of human lactoferrin. Antimicrob.
Agents Chemother. 54, 418–425. doi: 10.1128/AAC.00908-09
Hunter, H. N., Demcoe, A. R., Jenssen, H., Gutteberg, T. J., and Vogel, H. J.
(2005). Human lactoferricin is partially folded in aqueous solution and is better
stabilized in a membrane mimetic solvent. Antimicrob. Agents Chemother. 49,
3387–3395. doi: 10.1128/AAC.49.8.3387-3395.2005
Iigo, M., Alexander, D. B., Long, N., Xu, J., Fukamachi, K., Futakuchi, M., et al.
(2009). Anticarginogenesis pathways activated by bovine lactoferrin in the
murine small intestine. Biochimie 91, 86–101. doi: 10.1016/j.biochi.2008.06.012
Jameson, G. B., Anderson, B. F., Norris, G. E., Thomas, D. H., and Baker, E. N.
(1998). Structure of human apolactoferrin at 2.0 A resolution. Refinement and
analysis of ligand-induced conformational change. Acta Crystallogr. D Biol.
Crystallogr. 54, 1319–1335. doi: 10.1107/S0907444998004417
Jenssen, H., and Hancock, R. E. (2009). Antimicrobial properties of lactoferrin.
Biochimie 91, 19–29. doi: 10.1016/j.biochi.2008.05.015
Kullberg, B. J., Netea, M. G., Vonk, A. G., and Van der Meer, J. W. (1999).
Modulation of neutrophil function in host defense against disseminated
Candida albicans infection in mice. FEMS Immunol. Med. Microbiol. 26,
299–307. doi: 10.1111/j.1574-695X.1999.tb01402.x
Kirkpatrick, C. H., Green, I., Rich, R. R., and Schade, A. L. (1971). Inhibition of
growth of Candida albicans by iron-unsaturated lactoferrin: relation to host-
defence mechanisms in chronic mucocutaneous candidiasis. J. Infect. Dis. 125,
539–544. doi: 10.1093/infdis/124.6.539
Kobayashi, T., Kakeya, H., Miyazaki, T., Izumikawa, K., Yanagihara, K., Ohno, H.,
et al. (2011). Synergistic antifungal effect of lactoferrin with azole antifungals
against Candida albicans and a proposal for a new treatment method for
invasive candidiasis. Jpn. J. Infect. Dis. 64, 292–296.
Kondori, N., Baltzer, L., Dolphin, G. T., and Mattsby-Baltzer, I. (2011).
Fungicidal activity of human lactoferrin-derived peptides based on the
antimicrobial alphabeta region. Int. J. Antimicrob. Agents 37, 51–57.
doi: 10.1016/j.ijantimicag.2010.08.020
Kruzel, M. L., Bacsi, A., Choudhury, B., Sur, S., and Boldogh, I.
(2006). Lactoferrin decreases pollen antigen-induced allergic airway
inflammation in a murine model of asthma. Immunology 119, 159–166.
doi: 10.1111/j.1365-2567.2006.02417.x
Kuipers, M. E., de Vries, H. G., Eikelboom, M. C., Meijer, D. K., and Swart,
P. J. (1999). Synergistic fungistatic effects of lactoferrin in combination
with antifungal drugs against clinical Candida isolates. Antimicrob. Agents
Chemother. 43, 2635–2641.
Lahoz, E., Pisacane, A., Iannaccone, M., Palumbo, D., and Capparelli, R.
(2008). Fungistatic activity of iron-free bovin lactoferrin against several
fungal plant pathogens and antagonists. Nat. Prod. Res. 22, 955–961.
doi: 10.1080/14786410701650253
Lai, Y. W., Campbell, L. T., Wilkins, M. R., Pang, C. N., Chen, S., and
Carter, D. A. (2016). Synergy and antagonism between iron chelators and
antifungal drugs in Cryptococcus. Int. J. Antimicrob. Agents 48, 388–394.
doi: 10.1016/j.ijantimicag.2016.06.012
Leboffe, L., Giansanti, F., and Antonini, G. (2009). Antifungal and antiparasitic
activites of lactoferrin. Antiinfect. Agents Med. Chem. 8, 114–127.
doi: 10.2174/187152109787846105
Liceaga-Gesualdo, A., Li-Chan, E. C., and Skura, B. J. (2001). Antimicrobial
effect of lactoferrin digest on spores of a Penicillium sp. isolated from
bottled water. Food Res. Int. 34, 501–506. doi: 10.1016/S0963-9969(00)
00180-0
Lönnerdal, B., and Iyer, S. (1995). Lactoferrin: molecular structure
and biological function. Annu. Rev. Nutr. 44, 3257–3263.
doi: 10.1146/annurev.nu.15.070195.000521
Lupetti, A., Paulusma-Annema, A., Welling, M. M., Dogterom-Ballering,
H., Brouwer, C. P., Senesi, S., et al. (2003). Synergistic activity
of the N-terminal peptide of human lactoferrin and fluconazole
against Candida species. Antimicrob. Agents Chemother. 47, 262–267.
doi: 10.1128/AAC.47.1.262-267.2003
Lupetti, A., Paulusma-Annema, A., Welling, M. M., Senesi, S., van Dissel, J. T., and
Nibbering, P. H. (2000). Candidacidal activities of human lactoferrin peptides
derived from the N terminus. Antimicrob. Agents Chemother. 44, 3257–3263.
doi: 10.1128/AAC.44.12.3257-3263.2000
Lupetti, A., van Dissel, J. T., Brouwer, C. P., and Nibbering, P. H. (2008). Human
antimicrobial peptides’ antifungal activity against Aspergillus fumigatus. Eur.
J. Clin. Microbiol. Infect. Dis. 27, 1125–1129. doi: 10.1007/s10096-008-
0553-z
Masson, P. L., Heremans, J. F., and Ferin, J. (1968). Presence of an iron-
binding protein (lactoferrin) in the genital tract of the human female. I.
Its immunohistochemical localization in the endometrium. Fertil. Steril. 19,
679–689. doi: 10.1016/S0015-0282(16)36781-4
Mishra, B., Leishangthem, G. D., Gill, K., Singh, A. K., Das, S., Singh, K., et al.
(2013). A novel antimicrobial peptide derived from modified N-terminal
domain of bovine lactoferrin: design, synthesis, activity against multidrug-
resistant bacteria and Candida. Biochim. Biophys. Acta 1828, 677–686.
doi: 10.1016/j.bbamem.2012.09.021
Frontiers in Microbiology | www.frontiersin.org 9 January 2017 | Volume 8 | Article 2
Fernandes and Carter Antifungal Activity of Lactoferrin and Its Peptides
Muñoz, A., and Marcos, J. F. (2006). Activity and mode of action against fungal
phytopathogens of bovine lactoferricin-derived peptides. J. Appl. Microbiol.
101, 1199–1207. doi: 10.1111/j.1365-2672.2006.03089.x
Naidu, A. S., Fowler, R. S., Martinez, C., Chen, J., and Tulpinski, J. (2004). Activated
lactoferrin and fluconazole synergism against Candida albcians and Candida
glabrata vaginal isolates. J. Reprod. Med. 49, 800–807.
Nikawa, H., Samaranayake, L. P., Tenovuo, J., Pang, K. M., and Hamada, T. (1993).
The fungicidal effect of human lactoferrin on Candida albicans and Candida
krusei. Arch. Oral Biol. 38, 1057–1063. doi: 10.1016/0003-9969(93)90167-K
Ogasawara, Y., Imase, M., Oda, H., Wakabayashi, H., and Ishii, K. (2014).
Lactoferrin directly scavenges hydroxyl radicals and undergoes oxidative self-
degradation: a possible role in protection against oxidative DNA damage. Int. J.
Mol. Sci. 15, 1003–1013. doi: 10.3390/ijms15011003
Park, J. H., Park, G. T., Cho, I. H., Sim, S. M., Yang, J. M., and Lee, D. Y. (2011).
An antimicrobial protein, lactoferrin exists in the sweat: proteomic analysis of
sweat. Exp. Dermatol. 20, 369–371. doi: 10.1111/j.1600-0625.2010.01218.x
Sánchez-Gómez, S., Lamata, M., Leiva, J., Blondelle, S. E., Jerala, R.,
Andra, J., et al. (2008). Comparative analysis of selected methods for
the assessment of antimicrobial and membrane-permeabilizing activity:
a case study for lactoferricin derived peptides. BMC Microbiol. 8:196.
doi: 10.1186/1471-2180-8-196
Silva, T., Adao, R., Nazmi, K., Bolscher, J. G., Funari, S. S., Uhrikova, D., et al.
(2013). Structural diversity and mode of action on lipid membranes of three
lactoferrin candidacidal peptides. Biochim. Biophys. Acta 1828, 1329–1339.
doi: 10.1016/j.bbamem.2013.01.022
Sinha, M., Kaushik, S., Kaur, P., Sharma, S., and Singh, T. P. (2013). Antimicrobial
lactoferrin peptides: the hidden players in the protective function of a
multifunctional protein. Int. J. Pept. 2013:390230. doi: 10.1155/2013/390230
Sorensen, M., and Sorensen, S. P. L. (1939). The proteins of whey. Compt. Rend.
Trav. Lab. Carlsberg Ser. Chim. 23, 35–99.
Ueta, E., Tanida, T., and Osaki, T. (2001). A novel bovine lactoferrin peptide,
FKCRRWQWRM, suppresses Candida cell growth and activates neutrophils.
J. Pept. Res. 57, 240–249. doi: 10.1111/j.1399-3011.2001.00821.x
van der Does, A. M., Joosten, S. A., Vroomans, E., Bogaards, S. J., vanMeijgaarden,
K. E., Ottenhoff, T. H., et al. (2012). The antimicrobial peptide hLF1-11 drives
monocyte-dendritic cell differentiation toward dendritic cells that promote
antifungal responses and enhance Th17 polarization. J. Innate Immun. 4,
284–292. doi: 10.1159/000332941
van der Kraan, M. I., Groenink, J., Nazmi, K., Veerman, E. C., Bolscher, J. G.,
and Nieuw Amerongen, A. V. (2004). Lactoferrampin: a novel antimicrobial
peptide in the N1-domain of bovine lactoferrin. Peptides 25, 177–183.
doi: 10.1016/j.peptides.2003.12.006
van der Kraan, M. I., Van der Made, C., Nazmi, K., Van’t Hof, W., Groenink,
J., Veerman, E. C., et al. (2005a). Effect of amino acid substitutions on
the candidacidal activity of LFampin 265-284. Peptides 26, 2093–2097.
doi: 10.1016/j.peptides.2005.03.056
van der Kraan, M. I., Van Marle, J., Nazmi, K., Groenink, J., Van ’t Hof, W.,
Veerman, E. C., et al. (2005b). Ultrastructural effects of antimicrobial peptides
from bovine lactoferrin on the membranes of Candida albicans and Escherichia
coli. Peptides 26, 1537–1542. doi: 10.1016/j.peptides.2005.02.011
van der Strate, B. W., Belijaars, L., Molema, G., Harmsen, M. C., and Meijer,
D. K. (2001). Antiviral activites of lactoferrin. Antiviral Res. 52, 225–239.
doi: 10.1016/S0166-3542(01)00195-4
Venkatesh, M. P., and Rong, L. (2008). Human recombinant lactoferrin acts
synergistically with antimicrobials commonly used in neonatal practice against
coagulase-negative staphylococci andCandida albicans causing neonatal sepsis.
J. Med. Microbiol. 57, 1113–1121. doi: 10.1099/jmm.0.2008/001263-0
Viejo-Díaz, M., Andres, M. T., and Fierro, J. F. (2004). Modulation
of in vitro fungicidal activity of human lactoferrin against Candida
albicans by extracellular cation concentration and target cell
metabolic activity. Antimicrob. Agents Chemother. 48, 1242–1248.
doi: 10.1128/AAC.48.4.1242-1248.2004
Viejo-Diaz, M., Andres, M. T., and Fierro, J. F. (2005). Different anti-
Candida activities of two human lactoferrin-derived peptides, Lfpep
and Kaliocin-1. Antimicrob. Agents Chemother. 49, 2583–2588.
doi: 10.1128/AAC.49.7.2583-2588.2005
Wakabayashi, H., Abe, S., Okutomi, T., Tansho, S., Kawase, K., and Yamaguchi,
H. (1996). Cooperative anti-Candida effects of lactoferrin or its peptides in
combination with azole antifungal agents. Microbiol. Immunol. 40, 821–825.
doi: 10.1111/j.1348-0421.1996.tb01147.x
Wakabayashi, H., Abe, S., Teraguchi, S., Hayasawa, H., and Yamaguchi, H. (1998).
Inhibition of hyphal growth of azole-resistant strains of Candida albicans by
triazole antifungal agents in the presence of lactoferrin-related compounds.
Antimicrob. Agents Chemother. 42, 1587–1591.
Wakabayashi, H., Matsumoto, H., Hashimoto, K., Teraguchi, S., Takase, M.,
and Hayasawa, H. (1999). N-acylated and D enantiomer derivatives of a
nonamer core peptide of lactoferricin B showing improved antimicrobial
activity. Antimicrob. Agents Chemother. 43, 1267–1269.
Xu, Y., Wang, Y., Yan, L., Liang, R. M., Dai, B. D., Tang, R. J., et al.
(2009). Proteomic analysis reveals a synergistic mechanism of fluconazole
and berberine against fluconazole-resistant Candida albicans: endogenous ROS
augmentation. J. Proteome Res. 8, 5296–5304. doi: 10.1021/pr9005074
Xu, Y. Y., Samaranayake, Y. H., Samaranayake, L. P., and Nikawa, H. (1998). In
vitro susceptibility of Candida species to lactoferrin. Med. Mycol. 37, 35–41.
doi: 10.1080/02681219980000051
Zarember, K. A., Sugui, J. A., Chang, Y. C., Kwon-Chung, K. J., and Gallin, J.
I. (2007). Human polymorphonuclear leukocytes inhibit Aspergillus fumigatus
conidial growth by lactoferrin-mediated iron depletion. J. Immunol. 178,
6367–6373. doi: 10.4049/jimmunol.178.10.6367
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2017 Fernandes and Carter. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 10 January 2017 | Volume 8 | Article 2
